Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Willeit P, et al. Among authors: olsson ag. Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293769 Free article.
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Tsimikas S, et al. Among authors: olsson ag. Circulation. 2004 Sep 14;110(11):1406-12. doi: 10.1161/01.CIR.0000141728.23033.B5. Epub 2004 Sep 7. Circulation. 2004. PMID: 15353498 Clinical Trial.
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Schwartz GG, et al. Among authors: olsson ag. Diabetes Care. 2005 Oct;28(10):2508-13. doi: 10.2337/diacare.28.10.2508. Diabetes Care. 2005. PMID: 16186288 Clinical Trial.
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. Holme I, et al. Among authors: olsson ag. Ann Med. 2008;40(6):456-64. doi: 10.1080/07853890801964955. Ann Med. 2008. PMID: 19160529 Free article. Clinical Trial.
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Holme I, Strandberg TE, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Holme I, et al. Among authors: olsson ag. Atherosclerosis. 2009 Aug;205(2):522-7. doi: 10.1016/j.atherosclerosis.2009.01.023. Epub 2009 Jan 24. Atherosclerosis. 2009. PMID: 19327776 Clinical Trial.
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Fraley AE, et al. Among authors: olsson ag. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041. J Am Coll Cardiol. 2009. PMID: 19497447 Free article. Clinical Trial.
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Olsson AG, Lindahl C, Holme I, Fayyad R, Faergeman O, Kastelein JJ, Tikkanen MJ, Larsen ML, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Olsson AG, et al. Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):262-9. doi: 10.1177/1741826710389391. Epub 2011 Feb 8. Eur J Cardiovasc Prev Rehabil. 2011. PMID: 21450674 Clinical Trial.
315 results